-+ 0.00%
-+ 0.00%
-+ 0.00%

Innoscripta (XTRA:1INN) Stock May Be Below Fair Value On Clusterix Launch

Simply Wall St·11/19/2026 17:09:23
Listen to the news

Innoscripta has seen its share price fall sharply over the past year, and that slide puts a spotlight on a simple question for investors who still hold or are looking at the stock. Is the current market value supported by what the business earns today and what it can realistically earn over time?

  • The share price has declined 57.0% over the past year, which places the current valuation debate squarely on whether the earnings justify staying invested or stepping in now.
  • The recent launch of the Clusterix Transfer Pricing Suite may support expectations for future earnings by broadening the tax compliance offering and potentially deepening relationships with multinational clients.
  • The analysts covering innoscripta have run their own numbers. See what analysts think innoscripta's shares could be worth.

The issue now is whether innoscripta's current share price can be explained by its earnings profile when set against the Fair Ratio benchmark.

If you are weighing innoscripta after a 57.0% share price decline, it can help to compare its earnings story with other companies screened for 206 high quality undervalued stocks.

Does innoscripta Look Undervalued on Earnings?

The P/E ratio is a useful lens for innoscripta because earnings already matter to how investors are valuing the business. On this measure, the stock trades on roughly 7.9x earnings, compared with about 21.3x for the wider Software industry and around 23.9x for peers in the same valuation group.

Because the Fair Ratio framework tries to adjust for innoscripta's growth profile, profitability and risk, the current 7.9x level sits below what that model would usually flag for a business with similar traits. The launch of the Clusterix Transfer Pricing Suite may help explain why some investors see earnings power that is not fully reflected in today's P/E, even after the recent share price slide. This gap to both sector averages and the tailored benchmark points to a market that is pricing innoscripta at a lower earnings multiple than many comparable software stocks. Explore the numbers behind innoscripta's P/E valuation.

XTRA:1INN P/E Ratio as at Nov 2026
XTRA:1INN P/E Ratio as at Nov 2026

The innoscripta Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for innoscripta pick up where this valuation puzzle leaves off by spelling out which paths for future growth, profitability and earnings would need to play out for the stock to be worth meaningfully more or less than it is today, and they sit on the Community page. Each narrative links its number to a clear view on how innoscripta's growth, margins and risks might evolve, which you can revisit as fresh information comes through.

One of the top community narratives on innoscripta: 91% undervalued

According to European_Hidden_Gem_Stocks, an investor in the Simply Wall St Community, innoscripta looks more like a software platform than a niche tax adviser.

"Rather than charging subscriptions, the company earns a success fee only after customers receive funding, which means clients pay purely on results..."

Discover why this Narrative puts innoscripta at 91% undervalued.

Before deciding on innoscripta, there is one more angle to check

Valuation only tells part of the story for innoscripta, because Simply Wall St checks have flagged specific areas of concern that investors may want to review in detail before making a move. Take a closer look at 3 warning signs (2 major) before settling on a valuation.